Multi-parametric characterisation of peripheral immunity in recipients of checkpoint immunotherapy across a large patient cohort

转移性黑色素瘤以前预后不良，对化疗和放疗的敏感性低。然而，免疫检查点阻断（ICB）的引入彻底改变了治疗方法，极大地改善了生存结果。虽然广泛的研究调查了ICB对t细胞的影响，但对b细胞的影响较小。解剖b细胞对ICB的反应可以识别临床结果和自身免疫毒性的预测性标记。本项目的重点是探索b细胞和t细胞对ICB的反应，以及BCR/TCR谱的任何变化。此外，研究人员还探索了b细胞和t细胞的相互作用，以更好地了解其作用机制，并确定任何临床结果的预测指标。

Metastatic melanoma previously had poor prognostic outcome with low sensitivity to chemo- and radiotherapy treatments. However, the introduction of immune checkpoint blockade (ICB) revolutionised treatment massively improving survival outcomes. Whilst extensive studies have investigated the impact of ICB on T-cells, the effect on B-cells is less. Dissecting B-cell responses to ICB may discern predictive markers of clinical outcome and autoimmune toxicities. This project focuses upon exploring the response of both B-cells and T-cells to ICB as well as any changes induced in BCR/TCR repertoires. In addition, the interaction of B-cells and T-cells was explored to better understand the mechanism of action and identify any predictive markers of clinical outcome.